GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » Cash Flow from Investing

Tenax Therapeutics (Tenax Therapeutics) Cash Flow from Investing : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Tenax Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Tenax Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Tenax Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Tenax Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Cash Flow from Investing Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.02 0.45 - -

Tenax Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tenax Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Tenax Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Tenax Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tenax Therapeutics  (NAS:TENX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Tenax Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Tenax Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Tenax Therapeutics's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Tenax Therapeutics's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Tenax Therapeutics's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Tenax Therapeutics's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Tenax Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Tenax Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Tenax Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Tenax Therapeutics's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Tenax Therapeutics paid $0.00 Mil for other investing activities.


Tenax Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (Tenax Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

Tenax Therapeutics (Tenax Therapeutics) Headlines

From GuruFocus

Tenax Therapeutics Announces Reverse Stock Split

By Stock market mentor Stock market mentor 01-04-2023